11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Related posts

Together we are changing lives – Here’s how your support is making it happen

3 July 2025

Together we are changing lives – Here’s how your support is making it happen

At this point in our advocacy journey, we wanted to share an update to you, our supporters, on everything we’ve achieved so far and what’s next as we continue to…

Leukaemia UK appoints new Director of Communications job share from Shelter to lead their ambitious strategy

31 October 2022

Leukaemia UK appoints new Director of Communications job share from Shelter to lead their ambitious strategy

Blood cancer research charity, Leukaemia UK, has hired Anna Wilson and Lizzie Afonso from housing and homelessness charity, Shelter, to job-share its new Communications Director role. This is the first…

A new clinical trial announced

21 May 2020

A new clinical trial announced

A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

8 September 2022

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement: “We are extremely saddened to hear the news of the death of…